Pamela D Garzone Selected Research

RN909

11/2018

Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pamela D Garzone Research Topics

Disease

2	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 01/2020 - 02/2018
2	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 01/2020 - 12/2019
2	Hypercholesterolemia 02/2018 - 02/2018
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2020
1	Hypertension (High Blood Pressure) 01/2020
1	Type 2 Diabetes Mellitus (MODY) 11/2018
1	Diarrhea 11/2018
1	Neoplasms (Cancer) 10/2004
1	Melanoma (Melanoma, Malignant) 10/2004

Drug/Important Bio-Agent (IBA)

3	Proprotein Convertase 9IBA 01/2020 - 02/2018
2	monoclonal antibody RN168IBA 01/2020 - 12/2019
2	bococizumabIBA 02/2018 - 02/2018
1	LDL Receptors (LDL Receptor)IBA 01/2020
1	ApolipoproteinsIBA 01/2020
1	Apolipoproteins B (ApoB)IBA 01/2020
1	Interleukin-7 Receptors (Interleukin 7 Receptor)IBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	Triglycerides (Triacylglycerol)IBA 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2020
1	Interleukin-7 (Interleukin 7)IBA 12/2019
1	RN909IBA 11/2018
1	Monoclonal AntibodiesIBA 11/2018
1	Glucagon Receptors (Glucagon Receptor)IBA 11/2018
1	oxidized low density lipoproteinIBA 02/2018
1	Liposomes (Liposome)IBA 10/2004
1	IntegrinsIBA 10/2004
1	Integrin alphaVbeta3IBA 10/2004
1	cyclo(arginyl- glycyl- aspartyl- phenylalanyl- valyl)IBA 10/2004
1	Dextrans (Dextran)FDA Link 10/2004